{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.0","upperLimit":"20.2","value":"15.7"},{"groupId":"OG001","lowerLimit":"18.3","upperLimit":"47.3","value":"26.0"},{"groupId":"OG002","lowerLimit":"17.7","upperLimit":"18.4","value":"18.1"},{"comment":"N/A = Both lower and upper confidence intervals were not estimable as limited numbers of PD or death were observed.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"128"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Duration of response is the time from the first observed confirmed response (CR or PR) to disease progression or death due to any reason. Duration of response was for participants with ORR. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"The efficacy and safety of LDE225 200mg laBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG000","title":"LDE225 200mg laBCC"},{"description":"The efficacy and safety of LDE225 800mg laBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG001","title":"LDE225 800mg laBCC"},{"description":"The efficacy and safety of LDE225 200mg mBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG002","title":"LDE225 200mg mBCC"},{"description":"The efficacy and safety of LDE225 800mg mBCC cohort were analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.","id":"OG003","title":"LDE225 800mg mBCC"}],"paramType":"MEDIAN","populationDescription":"The full analysis set (FAS) comprised all patients who were assigned study treatment irrespective of receiving it (all randomized patients). Patients were classified according to the treatment they were assigned in accordance with the intention-to-treat (ITT) principle.","reportingStatus":"POSTED","timeFrame":"42 months","title":"Duration of Response (DoR) Per Site Investigator Review Using mRECIST for laBCC and RECIST 1.1 for mBCC (FAS)","type":"SECONDARY","unitOfMeasure":"Months"}